BRACAnalysis
This article was originally published in The Gray Sheet
Executive Summary
Myriad Genetic's breast and ovarian cancer genetic predisposition test is used in CLIA laboratories. It is not a CLIA-waived test, as was reported (1"The Gray Sheet" Sept. 16, 2002, p. 20)...
You may also be interested in...
Myriad Genetics DTC Ads For BRACAnalysis To Focus On Prevention Market
Myriad Genetics will concentrate direct-to-consumer advertising in Atlanta and Denver for its BRACAnalysis breast and ovarian cancer genetic predisposition testing service as the firm moves beyond physician education as a sole means of promotion
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.